- Home
- IRIX vs MTVA Comparison
IRIX vs MTVA Comparison
Compare IRIX & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- MTVA
- Stock Information
- Founded
- IRIX 1989
- MTVA 2014
- Country
- IRIX United States
- MTVA United States
- Employees
- IRIX N/A
- MTVA N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MTVA
- Sector
- IRIX Health Care
- MTVA
- Exchange
- IRIX Nasdaq
- MTVA NYSE
- Market Cap
- IRIX 16.5M
- MTVA 13.6M
- IPO Year
- IRIX 1996
- MTVA N/A
- Fundamental
- Price
- IRIX $1.22
- MTVA $0.82
- Analyst Decision
- IRIX Hold
- MTVA Strong Buy
- Analyst Count
- IRIX 1
- MTVA 1
- Target Price
- IRIX $2.00
- MTVA $12.00
- AVG Volume (30 Days)
- IRIX 98.8K
- MTVA 1.4M
- Earning Date
- IRIX 05-13-2025
- MTVA 05-08-2025
- Dividend Yield
- IRIX N/A
- MTVA N/A
- EPS Growth
- IRIX N/A
- MTVA N/A
- EPS
- IRIX N/A
- MTVA N/A
- Revenue
- IRIX $48,669,000.00
- MTVA N/A
- Revenue This Year
- IRIX $9.61
- MTVA N/A
- Revenue Next Year
- IRIX N/A
- MTVA N/A
- P/E Ratio
- IRIX N/A
- MTVA N/A
- Revenue Growth
- IRIX N/A
- MTVA N/A
- 52 Week Low
- IRIX $0.78
- MTVA $0.71
- 52 Week High
- IRIX $3.25
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- IRIX 62.01
- MTVA N/A
- Support Level
- IRIX $0.98
- MTVA N/A
- Resistance Level
- IRIX $1.26
- MTVA N/A
- Average True Range (ATR)
- IRIX 0.09
- MTVA 0.00
- MACD
- IRIX 0.04
- MTVA 0.00
- Stochastic Oscillator
- IRIX 91.49
- MTVA 0.00
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.